

Freedom of Information Request	FOI 21-385	5 <sup>th</sup> October 2021
--------------------------------	------------	------------------------------

**A. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Filgotinib**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Tofacitinib**
- **Ustekinumab**
- **Vedolizumab**

The Health Board is only able to supply information by quantity and not by the number of patients treated. The items dispensed by the pharmacy department, for gastroenterology, for the period June to August 2021 are provided overleaf.

**B. How many patients were treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:**

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilars**
- **Ustekinumab**
- **Vedolizumab**

The Health Board does not hold a register and would have to review every patient record to determine this. Therefore in order to comply with your request the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in access of 18 hours to review the record of each patient.



## DSUM - Drug Usage Summary Report

List of DECREASE transactions Monthly to August 2021 at All Locations by Drug (A Selection of Drugs ordered: Items within Group)

Decrease Transaction Types:

Inpatient Dispensed item

Day Case Dispensed item

Stock Adjustments via KADJ or KADJS

Requisitions via RTAKE

Returned Goods Out

Outpatient Dispensed item

One Stop Dispensed item

Stock Adjustments via KADJM

Raw Materials in Extemporaneous  
Dispensing  
Sale to Purchaser

compiled on ##### at #### by  
##

Jun Jul Aug

### USCD N101: Gastroenterology

ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Pen  
2 Pre-Filled Pen Pack

Quantity 304 285 269

ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled  
Syringe 2 Pre-Filled Syringe Pack

Quantity 7 5 4

ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Pen 2  
Pre-Filled Pen Pack

Quantity 10 6 4

GOLIMUMAB (SIMPONI) 100 mg in 1mL Pre-Filled Pen 1  
Pre-Filled Pen Pack

Quantity 0 2 2

INFLIXIMAB (INFLECTRA) 100 mg Intravenous Infusion 1  
Vial Pack

Quantity 512 479 490

TOFACITINIB 10 mg Tablets 56 Tablet Pack

Quantity 3 0 0

TOFACITINIB 5 mg Tablets 56 Tablet Pack

Quantity 6 0 0

USTEKINUMAB 130 mg in 26mL Intravenous Infusion 1 Vial  
Pack

Quantity 3 13 3

USTEKINUMAB 90 mg in 1mL Pre-Filled Syringe 1 Pre-Filled  
Syringe Pack

Quantity 27 24 43

VEDOLIZUMAB 108 mg in 0.68mL Pre-Filled Pen 1 Pre-  
Filled Pen Pack

Quantity 164 96 210

VEDOLIZUMAB 300 mg Intravenous Infusion 1 Vial LP Pack

Quantity 1 87 15

VEDOLIZUMAB 300 mg Intravenous Infusion 1 Vial Pack

Quantity 75 49 65

**Note: Credits included may relate to transaction types other than thoses selected. Quantities are shown rounded to whole packs. Values shown are the current values of the transactions.**